Hormonal
Tirzepatide (a dual GIP/GLP-1 receptor agonist) significantly improves hepatic steatosis and increases the likelihood of MASH resolution without worsening fibrosis in patients with non-cirrhotic MASH.
If you have MASH without cirrhosis, ask your doctor about tirzepatide. Clinical trials show that weekly injections of 5-15mg can significantly resolve MASH and improve liver fat without worsening fibrosis. This is a promising option for managing liver health in addition to blood sugar and weight.
The 52-week SYNERGY-NASH trial (NCT04166773) demonstrated that tirzepatide significantly increased the likelihood of resolution of biopsy-proven MASH compared to placebo in a dose-dependent manner and without worsening of moderate or severe fibrosis [68]. Specifically, 44% of participants in the 5 mg tirzepatide group, 56% in the 10 mg tirzepatide group, and 62% in the 15 mg tirzepatide group achieved MASH resolution, compared to just 10% in the placebo group.
Why this rating
Based on a Phase 2 randomized controlled trial (SYNERGY-NASH) with biopsy-proven outcomes, though limited to non-cirrhotic patients.
Source
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac et al. · Journal of Clinical Medicine · 2025
DOI 10.3390/jcm14041042
More from this paper
- Resmetirom is approved for adults with non-cirrhotic MASH and advanced liver fibrosis (stage ≥ 2) and has shown histological efficacy in addressing steatohepatitis and fibrosis.Good
- GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →